Allurion Technologies, Inc. (ALUR)

Allurion Technologies' stock (ALUR) experienced a significant decline of 84.58% between January 24, 2025, and January 23, 2026, and underwent a 1-25 reverse stock split on January 3, 2025. On February 3, 2026, Allurion announced a partnership to offer combination therapy with Mounjaro® (tirzepatide) at discounted prices. Preliminary unaudited results for the fourth quarter and full year 2025, announced on January 12, 2026, indicated a 22% to 37% increase in revenue quarter-over-quarter and approximately $15 million for the full year, alongside substantial improvements in operating expenses and losses. On November 25, 2025, Allurion reported initial results on combining the Allurion Program with low-dose tirzepatide to optimize muscle mass and GLP-1 adherence. A new peer-reviewed publication demonstrating superior weight loss and improved body composition with the Allurion Smart Capsule was announced on November 20, 2025. A strategic distribution partnership with ProSurg Medical in Brazil was announced on November 19, 2025. The company reported its third-quarter 2025 financial results on November 12, 2025, with revenue of $2.66 million, beating analyst expectations, and a narrowed operating loss. Insider selling also occurred, with Director Michael R. Davin selling shares in December 2025, and the stock has shown volatility over the past three months.

Specific detailed information regarding the demand seasonality for Allurion Technologies, Inc. products and services is not explicitly provided. While tools are available to identify seasonal patterns in ALUR's monthly returns, the actual patterns are not disclosed.

Allurion Technologies, Inc. is a HealthTech and medical device company focused on medical weight loss and bariatric surgery. Its primary offering is the Allurion Program, featuring the Allurion Smart Capsule, a swallowable intragastric balloon that doesn't require surgery, endoscopy, or anesthesia. The program also includes the Allurion Virtual Care Suite, which offers AI-powered remote patient monitoring tools and integrates with the Allurion Mobile App, Allurion Insights, and Allurion Connected Scale and Health Tracker devices. The Virtual Care Suite can be used independently of the Allurion Program to manage various weight-loss therapies.

Allurion Technologies, Inc. has an international presence with its corporate office in Paris, France, and headquarters in Natick, Massachusetts. The company operates in countries such as Spain, France, and Turkey, and its products have been used by over 100,000 patients in more than 50 countries across six continents. The Allurion Balloon has also received approval in Canada, Mexico, Australia, and India.

Allurion Technologies has maintained a positive brand reputation as a "pioneer in metabolically healthy weight loss." Key events contributing to its reputation include the publication of new peer-reviewed studies demonstrating the effectiveness of its Smart Capsule and the announcement of strategic partnerships, such as the one with Bionut in Argentina to offer combination therapy with Mounjaro. These developments highlight the company's commitment to innovation and patient outcomes in the weight loss field.

Allurion Technologies, Inc. has a diverse ownership structure. Major institutional owners include RTW Investments, L.P., Lunt Capital Management, Inc., UBS Group AG, Vanguard Group Inc., Unisphere Establishment, Geode Capital Management, LLC, BlackRock, Inc., and State Street Corp. Hedge fund managers collectively hold a significant portion of the shares, accounting for 47.98% of shares outstanding. Individual and insider owners include Shantanu Gaur (Co-Founder, CEO, President), Michael R. Davin (Independent Director), and Krishna Gupta.